دورية أكاديمية
أعرض في EDS

Melatonin and oral diseases: possible therapeutic roles based on cellular mechanisms.

التفاصيل البيبلوغرافية
العنوان: Melatonin and oral diseases: possible therapeutic roles based on cellular mechanisms.
المؤلفون: Hosseinzadeh A; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran., Jamshidi Naeini A; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran., Sheibani M; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran., Gholamine B; Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Reiter RJ; Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX, USA., Mehrzadi S; Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran. Sa_mehrzadi@yahoo.com.
المصدر: Pharmacological reports : PR [Pharmacol Rep] 2024 Jun; Vol. 76 (3), pp. 487-503. Date of Electronic Publication: 2024 Apr 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101234999 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2299-5684 (Electronic) Linking ISSN: 17341140 NLM ISO Abbreviation: Pharmacol Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : Cham, Switzerland : Springer International Publishing
Original Publication: Kraków, Poland : Institute of Pharmacology, Polish Academy of Sciences, c2005-
مواضيع طبية MeSH: Melatonin*/pharmacology , Melatonin*/therapeutic use , Mouth Diseases*/drug therapy, Humans ; Animals ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Oxidative Stress/drug effects ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use
مستخلص: Oral diseases, including periodontal disorders, oral cancer, periodontitis, and mucositis are the major challenges for both patients and healthcare providers. These conditions often involve inflammation, oxidative stress, and impaired cellular processes, leading to symptoms ranging from discomfort to severe debilitation. Conventional treatments for such oral diseases exhibit constraints, prompting the investigation of innovative therapeutic approaches. Considering the anti-inflammatory, anti-oxidant, and anti-cancer effects of melatonin, this study was carried out to investigate the potential protective effects of melatonin in mitigating the severity of oral diseases. Studies indicate that melatonin influences the differentiation of periodontal stem cells, inhibits oral cancer progression, reduces inflammation associated with periodontitis, and alleviates the severity of oral mucositis. Melatonin has demonstrated potential efficacy in both preclinical and clinical investigations; however, findings are frequently heterogeneous and contingent upon contextual factors. This review provides a comprehensiveoverview of current state of knowledge in this domain, elucidating the multifaceted role that melatonin may assume in combatingoral diseases. Further research should be directed toward determining the most effective dosing, timing, and administration methods for melatonin-based therapies for oral diseases.
(© 2024. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.)
References: Zhao D, Yu Y, Shen Y, Liu Q, Zhao Z, Sharma R, et al. melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol. 2019;10:249. (PMID: 10.3389/fendo.2019.00249)
Reiter RJ, Sharma R, Rosales-Corral S, de Campos Zuccari DAP, de Almeida Chuffa LG. Melatonin: a mitochondrial resident with a diverse skill set. Life Sci. 2022;301: 120612. (PMID: 3552328510.1016/j.lfs.2022.120612)
Hosseinzadeh A, Kamrava SK, Joghataei MT, Darabi R, Shakeri-Zadeh A, Shahriari M, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61:411–25. (PMID: 2755537110.1111/jpi.12362)
Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol. 2011;17:3888–98. (PMID: 22025877319801810.3748/wjg.v17.i34.3888)
Reiter RJ, Rosales-Corral SA, Liu XY, Acuna-Castroviejo D, Escames G, Tan DX. Melatonin in the oral cavity: physiological and pathological implications. J Periodontal Res. 2015;50:9–17. (PMID: 2466583110.1111/jre.12176)
Laakso ML, Porkka-Heiskanen T, Alila A, Stenberg D, Johansson G. Correlation between salivary and serum melatonin: dependence on serum melatonin levels. J Pineal Res. 1990;9:39–50. (PMID: 223127210.1111/j.1600-079X.1990.tb00692.x)
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15:434–43. (PMID: 28503116540561710.2174/1570159X14666161228122115)
Mehta A, Kaur G. Potential role of melatonin in prevention and treatment of oral carcinoma. Indian J Dent. 2014;5:86–91. (PMID: 25565731418432710.4103/0975-962X.135269)
Nijakowski K, Surdacki M, Sobieszczańska M. Salivary melatonin changes in oncological patients: a systematic review. Metabolites. 2022;12(5):439. (PMID: 35629943914781010.3390/metabo12050439)
Liu J, Huang F, He HW. Melatonin effects on hard tissues: bone and tooth. Int J Mol Sci. 2013;14:10063–74. (PMID: 23665905367682810.3390/ijms140510063)
Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin’s metabolites. AFMK and AMK J Pineal Res. 2013;54:245–57. (PMID: 22998574)
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–78. (PMID: 2750046810.1111/jpi.12360)
Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20–33. (PMID: 2920314810.1016/j.lfs.2017.12.001)
Juybari KB, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S. Melatonin potentials against viral infections including COVID-19: current evidence and new findings. Virus Res. 2020;287: 198108. (PMID: 10.1016/j.virusres.2020.198108)
Cengiz M, Cengiz S, Wang HL. Melatonin and oral cavity. Int J Dent. 2012;2012: 491872. (PMID: 22792106338967810.1155/2012/491872)
Wang L, Wang C, Choi WS. Use of melatonin in cancer treatment: where are we? Int J Mol Sci. 2022;23(7):3779. (PMID: 35409137899822910.3390/ijms23073779)
Meenakshi SS, Malaiappan S. Role of melatonin in periodontal disease - a systematic review. Indian J Dent Res. 2020;31:593–600. (PMID: 3310746310.4103/ijdr.IJDR_227_18)
Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”? Rev Med Virol. 2012;22:323–38. (PMID: 22511571716914410.1002/rmv.1714)
Anderson G, Reiter RJ. Melatonin: roles in influenza, covid-19, and other viral infections. Rev Med Virol. 2020;30: e2109. (PMID: 32314850723547010.1002/rmv.2109)
Najeeb S, Khurshid Z, Zohaib S, Zafar MS. Therapeutic potential of melatonin in oral medicine and periodontology. Kaohsiung J Med Sci. 2016;32:391–6. (PMID: 2752345110.1016/j.kjms.2016.06.005)
Cutando A, Aneiros-Fernández J, López-Valverde A, Arias-Santiago S, Aneiros-Cachaza J, Reiter RJ. A new perspective in oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch Oral Biol. 2011;56:944–50. (PMID: 2145936210.1016/j.archoralbio.2011.03.004)
Pourhanifeh MH, Mehrzadi S, Hosseinzadeh A. Melatonin and regulation of miRNAs: novel targeted therapy for cancerous and noncancerous disease. Epigenomics. 2021;13:65–81. (PMID: 3335086210.2217/epi-2020-0241)
Pourhanifeh MH, Mehrzadi S, Kamali M, Hosseinzadeh A. Melatonin and gastrointestinal cancers: current evidence based on underlying signaling pathways. Eur J Pharmacol. 2020;886: 173471. (PMID: 3287765810.1016/j.ejphar.2020.173471)
Mehrzadi MH, Hosseinzadeh A, Juybari KB, Mehrzadi S. Melatonin and urological cancers: a new therapeutic approach. Cancer Cell Int. 2020;20:1–11.
Mehrzadi S, Pourhanifeh MH, Mirzaei A, Moradian F, Hosseinzadeh A. An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress. Cancer Cell Int. 2021;21:1–28. (PMID: 10.1186/s12935-021-01892-1)
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu MM, Stoian AP, Jinga V, Nitipir C, et al. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncol Lett. 2020;19:1537–43. (PMID: 31966079)
Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19:1410–8. (PMID: 2479271910.1016/j.drudis.2014.04.014)
Mehrzadi S, Hemati K, Reiter RJ, Hosseinzadeh A. Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. Expert Opin Ther Targets. 2020;24:359–78. (PMID: 3211605610.1080/14728222.2020.1737015)
Mehrzadi S, Safa M, Kamrava SK, Darabi R, Hayat P, Motevalian M. Protective mechanisms of melatonin against hydrogen-peroxide-induced toxicity in human bone-marrow-derived mesenchymal stem cells. Can J Physiol Pharmacol. 2017;95:773–86. (PMID: 2817767810.1139/cjpp-2016-0409)
Mehrzadi S, Karimi MY, Fatemi A, Reiter RJ, Hosseinzadeh A. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin. Pharmacol Ther. 2021;224: 107825. (PMID: 33662449791958510.1016/j.pharmthera.2021.107825)
Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci. 2007;52:11–28. (PMID: 18217386)
Bagherifard A, Hosseinzadeh A, Koosha F, Sheibani M, Karimi-Behnagh A, Reiter RJ, et al. Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects. Osteoporos Int. 2023;34(10):1677–701. (PMID: 3739358010.1007/s00198-023-06836-1)
Bahrami N, Goudarzi M, Hosseinzadeh A, Sabbagh S, Reiter RJ, Mehrzadi S. Evaluating the protective effects of melatonin on di (2-ethylhexyl) phthalate-induced testicular injury in adult mice. Biomed Pharmacother. 2018;108:515–23. (PMID: 3024308410.1016/j.biopha.2018.09.044)
Hosseinzadeh A, Javad-Moosavi SA, Reiter RJ, Hemati K, Ghaznavi H, Mehrzadi S. Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin. Life Sci. 2018;201:17–29. (PMID: 2956707710.1016/j.lfs.2018.03.032)
Reiter R, Tang L, Garcia JJ, Muñoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 1997;60:2255–71. (PMID: 919468110.1016/S0024-3205(97)00030-1)
Reiter RJ, Sainz RM, LOPEZ-BURILLO S, Mayo JC, Manchester LC, Tan DX. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. Ann N Y Acad Sci. 2003;993:35–47. (PMID: 1285329310.1111/j.1749-6632.2003.tb07509.x)
Reiter RJ, Tan D-X. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 2003;58:10–9. (PMID: 1266794210.1016/S0008-6363(02)00827-1)
Mehrzadi S, Kamrava SK, Dormanesh B, Motevalian M, Hosseinzadeh A, Hosseini Tabatabaei SMT, et al. Melatonin synergistically enhances protective effect of atorvastatin against gentamicin-induced nephrotoxicity in rat kidney. Can J Physiol Pharmacol. 2016;94:265–71. (PMID: 2676262110.1139/cjpp-2015-0277)
Hosseinzadeh A, Dehdashtian E, Jafari-Sabet M, Mehrzadi S. The effects of vitamin D3 and melatonin combination on pentylenetetrazole-induced seizures in mice. Cent Nerv Syst Agents Med Chem. 2022;22:118–24. (PMID: 3550779010.2174/1871524922666220429121253)
Sewerynek E, Melchiorri D, Ortiz GG, Poeggeler B, Reiter RJ. Melatonin reduces H2O2-induced lipid peroxidation in homogenates of different rat brain regions. J Pineal Res. 1995;19:51–6. (PMID: 860959510.1111/j.1600-079X.1995.tb00170.x)
Pierrefiche G, Topall G, Courboin G, Henriet I, Laborit H. Antioxidant activity of melatonin in mice. Res Commun Chem Pathol Pharmaco. 1993;80:211–23.
Melchiorri D, Reiter RJ, Attia AM, Hara M, Burgos A, Nistico G. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci. 1995;56:83–9. (PMID: 782376210.1016/0024-3205(94)00417-Q)
Reiter RJ, Sewerynek E, Poeggeler B, Leal BZ, Meltz ML. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiat Res. 1995;143:102–6. (PMID: 759713610.2307/3578932)
Vijayalaxmi, Reiter RJ, Meltz ML. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res. 1995;346:23–31. (PMID: 753032610.1016/0165-7992(95)90065-9)
Hemati K, Pourhanifeh MH, Dehdashtian E, Fatemi I, Mehrzadi S, Reiter RJ, et al. Melatonin and morphine: potential beneficial effects of co-use. Fundam Clin Pharmacol. 2021;35:25–39. (PMID: 3241569410.1111/fcp.12566)
Hosseinzadeh A, Pourhanifeh MH, Amiri S, Sheibani M, Irilouzadian R, Reiter RJ, et al. Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis. Pharmacol Rep. 2024;76(1):25–50. (PMID: 3799508910.1007/s43440-023-00554-5)
Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int. 1995;26:497–502. (PMID: 749294710.1016/0197-0186(94)00154-M)
Pablos MI, Reiter RJ, Ortiz GG, Guerrero JM, Agapito MT, Chuang JI, et al. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int. 1998;32:69–75. (PMID: 946070410.1016/S0197-0186(97)00043-0)
Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006;40:168–76. (PMID: 1644155410.1111/j.1600-079X.2005.00295.x)
Hardeland R. Melatonin and inflammation—story of a double-edged blade. J Pineal Res. 2018;65: e12525. (PMID: 3024288410.1111/jpi.12525)
Hardeland R. Opposite effects of melatonin in different systems and under different conditions. Curr Top Biochem Res. 2016;17:57–69.
Morrey KM, McLachlan JA, Serkin CD, Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J Immunol. 1994;153:2671–80. (PMID: 807767410.4049/jimmunol.153.6.2671)
Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189–200. (PMID: 1621713210.1385/ENDO:27:2:189)
Garcia-Mauriño S, Gonzalez-Haba MG, Calvo JR, Goberna R, Guerrero JM. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol. 1998;92:76–84. (PMID: 991688210.1016/S0165-5728(98)00179-9)
Sener G, Toklu H, Kapucu C, Ercan F, Erkanli G, Kaçmaz A, et al. Melatonin protects against oxidative organ injury in a rat model of sepsis. Surg Today. 2005;35:52–9. (PMID: 1562246510.1007/s00595-004-2879-1)
Ozdemir D, Uysal N, Tugyan K, Gonenc S, Acikgoz O, Aksu I, et al. The effect of melatonin on endotoxemia-induced intestinal apoptosis and oxidative stress in infant rats. Intensive Care Med. 2007;33:511–6. (PMID: 1718628610.1007/s00134-006-0492-z)
Lowes DA, Almawash AM, Webster NR, Reid VL, Galley HF. Melatonin and structurally similar compounds have differing effects on inflammation and mitochondrial function in endothelial cells under conditions mimicking sepsis. Br J Anaesth. 2011;107:193–201. (PMID: 2165940510.1093/bja/aer149)
Doerrier C, García JA, Volt H, Díaz-Casado ME, Lima-Cabello E, Ortiz F, et al. Identification of mitochondrial deficits and melatonin targets in liver of septic mice by high-resolution respirometry. Life Sci. 2015;121:158–65. (PMID: 2549889910.1016/j.lfs.2014.11.031)
Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int J Endocrinol. 2017;2017:1835195. (PMID: 29104591564309810.1155/2017/1835195)
Álvarez-Sánchez N, Cruz-Chamorro I, Díaz-Sánchez M, Sarmiento-Soto H, Medrano-Campillo P, Martínez-López A, et al. Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients. J Pineal Res. 2017;63: e12442. (PMID: 10.1111/jpi.12442)
Wang C, Wang L, Wang X, Cao Z. Beneficial effects of melatonin on periodontitis management: far more than oral cavity. Int J Mol Sci. 2022;23:14541. (PMID: 36498871973929810.3390/ijms232314541)
Balaji TM, Vasanthi HR, Rao SR. Gingival, plasma and salivary levels of melatonin in periodontally healthy individuals and chronic periodontitis patients: a pilot study. J Clin Diagn Res. 2015;9:ZC23. (PMID: 259546994413149)
Tobeiha M, Jafari A, Fadaei S, Mirazimi SMA, Dashti F, Amiri A, et al. Evidence for the benefits of melatonin in cardiovascular disease. Front Cardiovasc Med. 2022;9:888319. (PMID: 35795371925134610.3389/fcvm.2022.888319)
Yu X, Li Z, Zheng H, Ho J, Chan MT, Wu WK. Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells. Cell Prolif. 2017;50: e12323. (PMID: 2794345910.1111/cpr.12323)
Mehrzadi S, Sheibani M, Koosha F, Alinaghian N, Pourhanifeh MH, Tabaeian SAP, et al. Protective and therapeutic potential of melatonin against intestinal diseases: updated review of current data based on molecular mechanisms. Expert Rev Gastroenterol Hepatol. 2023;17:1011–29. (PMID: 3779674610.1080/17474124.2023.2267439)
Suzuki N, Somei M, Seki A, Reiter RJ, Hattori A. Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases. J Pineal Res. 2008;45:229–34. (PMID: 1869135610.1111/j.1600-079X.2008.00623.x)
Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest. 1990;85:632–9. (PMID: 231271829647610.1172/JCI114485)
Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res. 2006;41:297–305. (PMID: 1701468610.1111/j.1600-079X.2006.00369.x)
Franchi M, Fini M, Martini D, Orsini E, Leonardi L, Ruggeri A, et al. Biological fixation of endosseous implants. Micron. 2005;36:665–71. (PMID: 1623397910.1016/j.micron.2005.05.010)
Cutando A, Arana C, Gómez-Moreno G, Escames G, López A, Ferrera MJ, et al. Local application of melatonin into alveolar sockets of beagle dogs reduces tooth removal-induced oxidative stress. J Periodontol. 2007;78:576–83. (PMID: 1733538310.1902/jop.2007.060244)
Permuy M, López-Peña M, González-Cantalapiedra A, Muñoz F. Melatonin: a review of its potential functions and effects on dental diseases. Int J Mol Sci. 2017;18:865. (PMID: 28422058541244610.3390/ijms18040865)
Battino M, Bullon P, Wilson M, Newman H. Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species. Crit Rev Oral Biol Med. 1999;10:458–76. (PMID: 1063458310.1177/10454411990100040301)
Almughrabi OM, Marzouk KM, Hasanato RM, Shafik SS. Melatonin levels in periodontal health and disease. J Periodontal Res. 2013;48:315–21. (PMID: 2303397410.1111/jre.12010)
Lodhi K, Saimbi CS, Khan MA, Nath C, Shukla R. Evaluation of melatonin levels in saliva in gingivitis and periodontitis cases: a pilot study. Contemp Clin Dent. 2016;7:519–23. (PMID: 27994421514166810.4103/0976-237X.194115)
Sankari M, Meenakshi SS. Melatonin in periodontal diseases: a review. Biomed Pharmacol J. 2019;12:3–6. (PMID: 10.13005/bpj/1607)
Xu Y, Qin W, Guo D, Liu J, Zhang M, Jin Z. LncRNA-TWIST1 promoted osteogenic differentiation both in PPDLSCs and in HPDLSCs by Inhibiting TWIST1 expression. Biomed Res Int. 2019;2019:8735952. (PMID: 31341908661238510.1155/2019/8735952)
Zhu W, Liang M. Periodontal ligament stem cells: current status, concerns, and future prospects. Stem Cells Int. 2015;2015: 972313. (PMID: 25861283437870510.1155/2015/972313)
Tan Y-Z, Xu X-Y, Dai J-M, Yin Y, He X-T, Zhang Y-L, et al. Melatonin induces the rejuvenation of long-term ex vivo expanded periodontal ligament stem cells by modulating the autophagic process. Stem Cell Res Ther. 2021;12:254. (PMID: 33926537808282410.1186/s13287-021-02322-9)
Balaji TM, Bandyopadhyay D, Venkatakrishnan C, Bhati AK, Rajendiran S. Melatonin could alleviate the dysregulation of metabolic reprogramming in periodontitis—implications in host modulatory therapy. WJOUD. 2021;12:166–70. (PMID: 10.5005/jp-journals-10015-1823)
Lee S, Le NH, Kang D. Melatonin alleviates oxidative stress-inhibited osteogenesis of human bone marrow-derived mesenchymal stem cells through AMPK activation. Int J Med Sci. 2018;15:1083. (PMID: 30013450603616110.7150/ijms.26314)
Zheng M, Zhang F, Fan W, Jiang L, Li J, Xie S, et al. Suppression of osteogenic differentiation and mitochondrial function change in human periodontal ligament stem cells by melatonin at physiological levels. PeerJ. 2020;8: e8663. (PMID: 32181054706075410.7717/peerj.8663)
Zhou L, Chen X, Yan J, Li M, Liu T, Zhu C, et al. Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS. Osteoporos Int. 2017;28:3325–37. (PMID: 28956094984150210.1007/s00198-017-4127-8)
Ni Z, Wang B, Dai X, Ding W, Yang T, Li X, et al. HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS–JNK–autophagy pathway. Free Radic Biol Med. 2014;70:194–203. (PMID: 2457650710.1016/j.freeradbiomed.2014.02.012)
Wang C, Wang L, Wang X, Cao Z. Beneficial Effects of melatonin on periodontitis management: far more than oral cavity. Int J Mol Sci. 2022;23(23):14541. (PMID: 36498871973929810.3390/ijms232314541)
Wang J, Qiao Q, Sun Y, Yu W, Wang J, Zhu M, et al. Osteogenic differentiation effect of human periodontal ligament stem-cell initial cell density on autologous cells and human bone marrow stromal cells. Int J Mol Sci. 2023;24(8):7133. (PMID: 371082961013898210.3390/ijms24087133)
Schröder A, Alefeld A, Forneck A, Spanier G, Deschner J, Proff P, et al. Impact of melatonin on periodontal ligament fibroblasts during mechanical strain. Eur J Orthod. 2022;44:659–68. (PMID: 3539699310.1093/ejo/cjac013)
Yu N, Zhang J, Han L, Na C, Yuan X. Melatonin promotes osteogenic differentiation in lipopolysaccharide-stimulated human periodontal ligament stem cells through bone morphogenic proteins-2-related signaling. J Biomater Tissue Eng. 2019;9:679–86. (PMID: 10.1166/jbt.2019.2032)
Min SK, Kim M, Park JB. Bone morphogenetic protein 2-enhanced osteogenic differentiation of stem cell spheres by regulation of Runx2 expression. Exp Ther Med. 2020;20:79. (PMID: 32968436749994810.3892/etm.2020.9206)
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. (PMID: 1947438510.3322/caac.20006)
Cutando A, Gómez-Moreno G, Arana C, Acuña-Castroviejo D, Reiter RJ. Melatonin: potential functions in the oral cavity. J Periodontol. 2007;78:1094–102. (PMID: 1753972410.1902/jop.2007.060396)
Di Bella G, Mascia F, Gualano L, Di Bella L. Melatonin anticancer effects: review. Int J Mol Sci. 2013;14:2410–30. (PMID: 23348932358799410.3390/ijms14022410)
Lissoni P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris). 2007;55:198–200. (PMID: 1745188910.1016/j.patbio.2006.12.008)
Seidman MD, Quirk WS, Shirwany NA. Reactive oxygen metabolites, antioxidants and head and neck cancer. Head Neck. 1999;21:467–79. (PMID: 1040252910.1002/(SICI)1097-0347(199908)21:5<467::AID-HED14>3.0.CO;2-C)
de Bree R, Leemans CR. Recent advances in surgery for head and neck cancer. Curr Opin Oncol. 2010;22:186–93. (PMID: 2017364010.1097/CCO.0b013e3283380009)
Moloudizargari M, Moradkhani F, Hekmatirad S, Fallah M, Asghari MH, Reiter RJ. Therapeutic targets of cancer drugs: modulation by melatonin. Life Sci. 2021;267: 118934. (PMID: 3338540510.1016/j.lfs.2020.118934)
Wang L, Su Y, Choi WS. Melatonin suppresses oral squamous cell carcinomas migration and invasion through blocking FGF19/FGFR 4 signaling pathway. Int J Mol Sci. 2021;22(18):9907. (PMID: 34576070846879310.3390/ijms22189907)
Alvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Bárcena-Varela M, Elizalde M, et al. Fibroblast growth factor 15/19 in hepatocarcinogenesis. Dig Dis. 2017;35:158–65. (PMID: 2824925910.1159/000450905)
Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eurasian J Med. 2016;48:135. (PMID: 27551178497055210.5152/eurasianjmed.2015.0267)
Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, et al. Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G-protein coupled state. Br J Pharmacol. 2014;171:186–201. (PMID: 2411700810.1111/bph.12457)
Park HK, Ryu MH, Hwang DS, Kim GC, Jang MA, Kim UK. Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients. Int J Oral Maxillofac Surg. 2022;51:713–23. (PMID: 3448302810.1016/j.ijom.2021.08.015)
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541. (PMID: 29362479586423910.1038/s41418-017-0012-4)
Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets. 2013;17:1483–96. (PMID: 2403264310.1517/14728222.2013.834890)
Wang L, Wang C, Li X, Tao Z, Zhu W, Su Y, et al. Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS. Cell Mol Biol Lett. 2023;28:36. (PMID: 371311521015531310.1186/s11658-023-00449-6)
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–31. (PMID: 748182010.1126/science.270.5240.1326)
Zhang Y, Wang B, Chen X, Li W, Dong P. AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells. Oncotarget. 2017;8:54735–46. (PMID: 28903378558961710.18632/oncotarget.18047)
Sung ES, Kim JY, Ahn YT, Lee IW, Choi SW, Jang HB, et al. Melatonin exerts anticancer effects in human tongue squamous cell carcinoma cells by promoting autophagy. Anticancer Res. 2020;40:6295–303. (PMID: 3310956710.21873/anticanres.14650)
Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001;61:6500–10. (PMID: 11522647)
Salarić I, Karmelić I, Lovrić J, Baždarić K, Rožman M, Čvrljević I, et al. Salivary melatonin in oral squamous cell carcinoma patients. Sci Rep. 2021;11:13201. (PMID: 34168230822587810.1038/s41598-021-92649-3)
Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118. (PMID: 3335398210.1038/s41580-020-00315-9)
Qian Y, Shi L, Luo Z. Long non-coding rnas in cancer: implications for diagnosis, prognosis, and therapy. Front Med (Lausanne). 2020;7: 612393. (PMID: 3333057410.3389/fmed.2020.612393)
Yang SF, Yeh CM. PO-351 melatonin suppresses TPA-induced oral cancer cell migration via lncRNA-LNC310-mediated PRUNE2 activation. ESMO Open. 2018;3:A366. (PMID: 10.1136/esmoopen-2018-EACR25.863)
Cheng J, Cheng A, Clifford BL, Wu X, Hedin U, Maegdefessel L, et al. MicroRNA-144 silencing protects against atherosclerosis in male, but not female mice. Arterioscler Thromb Vasc Biol. 2020;40:412–25. (PMID: 3185221910.1161/ATVBAHA.119.313633)
Xu H, Sun Y, You B, Huang CP, Ye D, Chang C. Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling. Cancer Lett. 2020;472:151–64. (PMID: 3184668910.1016/j.canlet.2019.12.014)
Zheng J, Xu T, Chen F, Zhang Y. MiRNA-195-5p functions as a tumor suppressor and a predictive of poor prognosis in non-small cell lung cancer by directly targeting CIAPIN1. Pathol Oncol Res. 2019;25:1181–90. (PMID: 3063758910.1007/s12253-018-0552-z)
Wang Y, Tao B, Li J, Mao X, He W, Chen Q. Melatonin inhibits the progression of oral squamous cell carcinoma via inducing miR-25-5p expression by directly targeting NEDD9. Front Oncol. 2020;10: 543591. (PMID: 33344223773862310.3389/fonc.2020.543591)
Konečná B, Chobodová P, Janko J, Baňasová L, Bábíčková J, Celec P, et al. The effect of melatonin on periodontitis. Int J Mol Sci. 2021;22(5):2390. (PMID: 33673616795769510.3390/ijms22052390)
Eke PI, Zhang X, Lu H, Wei L, Thornton-Evans G, Greenlund KJ, et al. Predicting periodontitis at state and local levels in the united states. J Dent Res. 2016;95:515–22. (PMID: 2684807110.1177/0022034516629112)
D’Aiuto F, Nibali L, Parkar M, Patel K, Suvan J, Donos N. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res. 2010;89:1241–6. (PMID: 20739696331802510.1177/0022034510375830)
Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontol. 2000;2007(43):160–232.
Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809–20. (PMID: 1629822010.1016/S0140-6736(05)67728-8)
Matthews JB, Wright HJ, Roberts A, Ling-Mountford N, Cooper PR, Chapple IL. Neutrophil hyper-responsiveness in periodontitis. J Dent Res. 2007;86:718–22. (PMID: 1765219810.1177/154405910708600806)
Yamamoto T, Tomofuji T, Tamaki N, Ekuni D, Azuma T, Sanbe T. Effects of topical application of lipopolysaccharide and proteases on hepatic injury induced by high-cholesterol diet in rats. J Periodontal Res. 2010;45:129–35. (PMID: 1960210510.1111/j.1600-0765.2009.01212.x)
Santonocito S, Polizzi A, Palazzo G, Isola G. The emerging role of microrna in periodontitis: pathophysiology, clinical potential and future molecular perspectives. Int J Mol Sci. 2021;22(11):5456. (PMID: 34064286819685910.3390/ijms22115456)
Olsen I, Singhrao SK, Osmundsen H. Periodontitis, pathogenesis and progression: miRNA-mediated cellular responses to Porphyromonas gingivalis. J Oral Microbiol. 2017;9:1333396. (PMID: 28748037550836510.1080/20002297.2017.1333396)
Stoecklin-Wasmer C, Guarnieri P, Celenti R, Demmer RT, Kebschull M, Papapanou PN. MicroRNAs and their target genes in gingival tissues. J Dent Res. 2012;91:934–40. (PMID: 22879578344683110.1177/0022034512456551)
Bagavad Gita J, George AV, Pavithra N, Chandrasekaran SC, Latchumanadhas K, Gnanamani A. Dysregulation of miR-146a by periodontal pathogens: a risk for acute coronary syndrome. J Periodontol. 2019;90:756–65. (PMID: 3061810010.1002/JPER.18-0466)
Motedayyen H, Ghotloo S, Saffari M, Sattari M, Amid R. Evaluation of MicroRNA-146a and its targets in gingival tissues of patients with chronic periodontitis. J Periodontol. 2015;86:1380–5. (PMID: 2631302010.1902/jop.2015.150319)
Zhou W, Su L, Duan X, Chen X, Hays A, Upadhyayula S, et al. MicroRNA-21 down-regulates inflammation and inhibits periodontitis. Mol Immunol. 2018;101:608–14. (PMID: 29884447618277010.1016/j.molimm.2018.05.008)
Akkouch A, Zhu M, Romero-Bustillos M, Eliason S, Qian F, Salem AK, et al. MicroRNA-200c attenuates periodontitis by modulating proinflammatory and osteoclastogenic mediators. Stem Cells Dev. 2019;28:1026–36. (PMID: 31017046666192210.1089/scd.2019.0027)
Lang NP, Adler R, Joss A, Nyman S. Absence of bleeding on probing. An indicator of periodontal stability. J Clin Periodontol. 1990;17:714–21. (PMID: 226258510.1111/j.1600-051X.1990.tb01059.x)
Joss A, Adler R, Lang NP. Bleeding on probing. A parameter for monitoring periodontal conditions in clinical practice. J Clin Periodontol. 1994;21:402–8. (PMID: 808924210.1111/j.1600-051X.1994.tb00737.x)
Haffajee AD, Socransky SS, Lindhe J, Kent RL, Okamoto H, Yoneyama T. Clinical risk indicators for periodontal attachment loss. J Clin Periodontol. 1991;18:117–25. (PMID: 200522510.1111/j.1600-051X.1991.tb01700.x)
van der Velden U, Abbas F, Hart AA. Experimental gingivitis in relation to susceptibility to periodontal disease. (I.) Clinical observations. J Clin Periodontol. 1985;12:61–8. (PMID: 385587210.1111/j.1600-051X.1985.tb01354.x)
Lu X, Yu S, Chen G, Zheng W, Peng J, Huang X, et al. Insight into the roles of melatonin in bone tissue and bone-related diseases (Review). Int J Mol Med. 2021;47(5):82. (PMID: 33760138797926010.3892/ijmm.2021.4915)
Maria S, Witt-Enderby PA. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J Pineal Res. 2014;56:115–25. (PMID: 2437264010.1111/jpi.12116)
Kose O, Arabaci T, Kara A, Yemenoglu H, Kermen E, Kizildag A, et al. Effects of melatonin on oxidative stress index and alveolar bone loss in diabetic rats with periodontitis. J Periodontol. 2016;87:e82-90. (PMID: 2683283310.1902/jop.2016.150541)
Balci Yuce H, Karatas O, Aydemir Turkal H, Pirim Gorgun E, Ocakli S, Benli I, et al. The effect of melatonin on bone loss, diabetic control, and apoptosis in rats with diabetes with ligature-induced periodontitis. J Periodontol. 2016;87:e35-43. (PMID: 2665434710.1902/jop.2015.150315)
Cutando A, López-Valverde A, de Diego RG, de Vicente J, Reiter R, Fernández MH, et al. Effect of topical application of melatonin to the gingiva on salivary osteoprotegerin, RANKL and melatonin levels in patients with diabetes and periodontal disease. Odontology. 2014;102:290–6. (PMID: 23934086)
Cutando A, López-Valverde A, Gómez-de-Diego R, Arias-Santiago S, de Vicente-Jiménez J. Effect of gingival application of melatonin on alkaline and acid phosphatase, osteopontin and osteocalcin in patients with diabetes and periodontal disease. Med Oral Patol Oral Cir Bucal. 2013;18:e657–63. (PMID: 23524437373109510.4317/medoral.18832)
Megavath S, Nagarakanti S, Chava VK. Effect of nonsurgical periodontal therapy on salivary melatonin levels in patients with periodontal disease. J Indian Soc Periodontol. 2023;27:154–9. (PMID: 371524611015909710.4103/jisp.jisp_392_21)
Balaji TM, Varadarajan S, Jagannathan R, Mahendra J, Fageeh HI, Fageeh HN, et al. Melatonin as a topical/systemic formulation for the management of periodontitis: a systematic review. Materials (Basel). 2021;14(9):2417. (PMID: 3406649810.3390/ma14092417)
Volpato LER, Silva TC, Oliveira TM, Sakai VT, Machado MAAM. Mucosite bucal rádio e quimioinduzida. Rev Bras Otorrinolaringol. 2007;73(4):562–8. (PMID: 10.1590/S0034-72992007000400017)
Bensadoun RJ, Magné N, Marcy PY, Demard F. Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol. 2001;258:481–7. (PMID: 1176999710.1007/s004050100368)
Abdel Moneim AE, Guerra-Librero A, Florido J, Shen YQ, Fernández-Gil B, Acuña-Castroviejo D, et al. Oral mucositis: melatonin gel an effective new treatment. Int J Mol Sci. 2017;18(5):1003. (PMID: 28481279545491610.3390/ijms18051003)
Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253–62. (PMID: 1274226410.1016/S0167-8140(02)00404-8)
Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–43. (PMID: 965951810.1016/S1368-8375(97)00053-5)
Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology (Williston Park). 1991;5:11–8. (PMID: 1840018)
Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004;2:3–8. (PMID: 15605918)
Ortiz F, Acuña-Castroviejo D, Doerrier C, Dayoub JC, López LC, Venegas C, et al. Melatonin blunts the mitochondrial/NLRP3 connection and protects against radiation-induced oral mucositis. J Pineal Res. 2015;58:34–49. (PMID: 2538891410.1111/jpi.12191)
Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84. (PMID: 1505728710.1038/nrc1318)
Tsutsui H, Imamura M, Fujimoto J, Nakanishi K. The TLR4/TRIF-mediated activation of NLRP3 inflammasome underlies endotoxin-induced liver injury in mice. Gastroenterol Res Pract. 2010;2010: 641865. (PMID: 20634907290444310.1155/2010/641865)
Fistarol SK, Itin PH. Anti-inflammatory treatment. Curr Probl Dermatol. 2011;40:58–70. (PMID: 2132584010.1159/000321051)
Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997–3025. (PMID: 2455405810.1007/s00018-014-1579-2)
Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S, et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med. 1999;27:838–47. (PMID: 1051558810.1016/S0891-5849(99)00131-8)
Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res. 2014;57:131–46. (PMID: 2506010210.1111/jpi.12162)
Kolli VK, Abraham P, Isaac B, Kasthuri N. Preclinical efficacy of melatonin to reduce methotrexate-induced oxidative stress and small intestinal damage in rats. Dig Dis Sci. 2013;58:959–69. (PMID: 2305390310.1007/s10620-012-2437-4)
Chahbouni M, Escames G, Venegas C, Sevilla B, García JA, López LC, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from duchenne muscular dystrophy. J Pineal Res. 2010;48:282–9. (PMID: 2021085410.1111/j.1600-079X.2010.00752.x)
Kedziora-Kornatowska K, Szewczyk-Golec K, Czuczejko J, Pawluk H, van de Marke LK, Kozakiewicz M, et al. Antioxidative effects of melatonin administration in elderly primary essential hypertension patients. J Pineal Res. 2008;45:312–7. (PMID: 1836367410.1111/j.1600-079X.2008.00592.x)
Tokuyama-Toda R, Umeki H, Okubo M, Terada-Ito C, Yudo T, Ide S, et al. The preventive effect of melatonin on radiation-induced oral mucositis. Cells. 2023;12(17):2178. (PMID: 376819101048727310.3390/cells12172178)
Tan DX, Zanghi BM, Manchester LC, Reiter RJ. Melatonin identified in meats and other food stuffs: potentially nutritional impact. J Pineal Res. 2014;57:213–8. (PMID: 2494209010.1111/jpi.12152)
Slominski AT, Kleszczyński K, Semak I, Janjetovic Z, Zmijewski MA, Kim TK, et al. Local melatoninergic system as the protector of skin integrity. Int J Mol Sci. 2014;15:17705–32. (PMID: 25272227422718510.3390/ijms151017705)
Varoni EM, Lo Faro AF, Lodi G, Carrassi A, Iriti M, Sardella A. Melatonin treatment in patients with burning mouth syndrome: a triple-blind, placebo-controlled, crossover randomized clinical trial. J Oral Facial Pain Headache. 2018;32:178–88. (PMID: 2969446510.11607/ofph.1913)
Luengtrakoon K, Wannakasemsuk W, Vichitrananda V, Klanrit P, Hormdee D, Noisombut R, et al. Increased melatonin in oral mucosal tissue of oral lichen planus (OLP) patients: a possible link between melatonin and its role in oral mucosal inflammation. Arch Oral Biol. 2017;78:13–9. (PMID: 2818988010.1016/j.archoralbio.2017.02.007)
Chaiyarit P, Luengtrakoon K, Wannakasemsuk W, Vichitrananda V, Klanrit P, Hormdee D, et al. Biological functions of melatonin in relation to pathogenesis of oral lichen planus. Med Hypotheses. 2017;104:40–4. (PMID: 2867358810.1016/j.mehy.2017.05.021)
Anton DM, Martu MA, Maris M, Maftei GA, Sufaru IG, Tatarciuc D, et al. Study on the effects of melatonin on glycemic control and periodontal parameters in patients with type II diabetes mellitus and periodontal disease. Medicina (Kaunas). 2021;57(2):140. (PMID: 3356245210.3390/medicina57020140)
Bazyar H, Zare Javid A, Zakerkish M, Yousefimanesh HA, Haghighi-Zadeh MH. Effects of melatonin supplementation in patients with type 2 diabetes mellitus and chronic periodontitis under nonsurgical periodontal therapy: a double-blind randomized controlled trial. J Res Med Sci. 2022;27:52. (PMID: 36092489945024910.4103/jrms.JRMS_927_19)
Köse O, Arabaci T, Kizildag A, Erdemci B, Özkal Eminoğlu D, Gedikli S, et al. Melatonin prevents radiation-induced oxidative stress and periodontal tissue breakdown in irradiated rats with experimental periodontitis. J Periodontal Res. 2017;52:438–46. (PMID: 2751043710.1111/jre.12409)
Chitsazi M, Faramarzie M, Sadighi M, Shirmohammadi A, Hashemzadeh A. Effects of adjective use of melatonin and vitamin C in the treatment of chronic periodontitis: a randomized clinical trial. J Dent Res Dent Clin Dent Prospects. 2017;11:236–40. (PMID: 293542505768956)
Virto L, Cano P, Jiménez-Ortega V, Fernández-Mateos P, González J, Haugen HJ, et al. Melatonin as adjunctive therapy in the treatment of periodontitis associated with obesity. J Clin Periodontol. 2018;45:1336–46. (PMID: 3024053510.1111/jcpe.13013)
Arabacı T, Kermen E, Özkanlar S, Köse O, Kara A, Kızıldağ A, et al. Therapeutic effects of melatonin on alveolar bone resorption after experimental periodontitis in rats: a biochemical and immunohistochemical study. J Periodontol. 2015;86:874–81. (PMID: 2581291110.1902/jop.2015.140599)
Onseng K, Johns NP, Khuayjarernpanishk T, Subongkot S, Priprem A, Hurst C, et al. Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med. 2017;23:957–63. (PMID: 2865780110.1089/acm.2017.0081)
Elsabagh HH, Moussa E, Mahmoud SA, Elsaka RO, Abdelrahman H. Efficacy of melatonin in prevention of radiation-induced oral mucositis: a randomized clinical trial. Oral Dis. 2020;26:566–72. (PMID: 3186985310.1111/odi.13265)
فهرسة مساهمة: Keywords: Inflammation; Melatonin; Oral diseases; Oxidative stress; Pharmacology
المشرفين على المادة: JL5DK93RCL (Melatonin)
0 (Antioxidants)
0 (Anti-Inflammatory Agents)
تواريخ الأحداث: Date Created: 20240412 Date Completed: 20240524 Latest Revision: 20240701
رمز التحديث: 20240702
DOI: 10.1007/s43440-024-00593-6
PMID: 38607587
قاعدة البيانات: MEDLINE
الوصف
تدمد:2299-5684
DOI:10.1007/s43440-024-00593-6